Virios Therapeutics to merge with Wex Pharmaceuticals to form Dogwood Therapeutics.

Virios Therapeutics, a biotechnology company, agreed to merge with Wex Pharmaceuticals, a pharmaceutical company, to form Dogwood Therapeutics, a pharmaceutical company. Financial terms were not disclosed. “This transaction represents our deep commitment to delivering value to stockholders by expanding our pipeline with a synergistic, novel program while also providing the upside opportunity for existing Virios stockholders to receive future cash payments through CVRs for potential licensing partnerships relating to IMC-1 and IMC-2. With the anticipated funding and an accomplished management team, we believe Dogwood is well-positioned to advance its programs by leveraging its FDA Fast Track designations for IMC-1 and Halneuron®,” Greg Duncan, Dogwood Therapeutics Chief Executive Officer.